HIV Vaccine Research Agenda: Perspectives of an HVTN Site Investigator

Similar Items

• Feasibility of recruiting high-risk women in the US for HIV vaccine efficacy trials (HVTN 906)
  by: Koblin B, et al.
  Published: (2012-09-01)
• P15-15. Advocates' perspectives on community engagement in the HVTN 505
  by: Miller L, et al.
  Published: (2009-10-01)
• Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120.
  by: Allan C deCamp, et al.
  Published: (2017-01-01)
• Predictors of HVTN 503 MRK-AD5 HIV-1 gag/pol/nef vaccine induced immune responses.
  by: Kathryn L Hopkins, et al.
  Published: (2014-01-01)
• Uptake of genital mucosal sampling in HVTN 097, a phase 1b HIV vaccine trial in South Africa.
  by: Erica Maxine Lazarus, et al.
  Published: (2014-01-01)